Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

GSK extended its collaboration with Chongqing Zhifei Biological Products to commercialize its shingles vaccine Shingrix in ...

UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

GSK PLCGSK3.09%increase; green up pointing triangle extended its collaboration with Chongqing Zhifei Biological Products 300122-1.12%decrease; red down pointing triangle to commercialize its ...

(RTTNews) - GSK plc (GSK, GSK.L), on Thursday, said it has agreed with Chongqing Zhifei Biological Products Ltd. to revise the terms on which Zhifei will commercialize GSK's shingles vaccine ...

Drugmaker GSK has revised and extended its strategic vaccine collaboration with Chinese firm Chongqing Zhifei Biological Products.